Pfizer’s Covid-19 vaccine sales forecasts upgraded with sales of $37bn in 2022
Pharmaceutical Technology
FEBRUARY 21, 2023
Pfizer and BioNTech’s Covid-19 vaccine, Comirnaty, had a phenomenal year with forecast sales of $37bn in 2022. Comirnaty is the leading prophylactic vaccine for Covid-19 and is expected to generate an additional $2.8bn in sales in 2022 compared to GlobalData’s H1 2022 forecast.
Let's personalize your content